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Duchenne muscular dystrophy (DMD) remains an
intractable genetic disease. Althogh there are several
animal models of DMD, there is no human cell model
that carries patient-specific DYSTROPHIN muta-
tions. Here, we present a human DMD model using
human induced pluripotent stem cells (hiPSCs). Our
model reveals concordant disease-related pheno-
types with patient-dependent variation, which are
partially reversed by genetic and pharmacological
approaches. Our ‘‘chemical-compound-based’’ strat-
egy successfully directs hiPSCs into expandable
myoblasts, which exhibit a myogenic transcriptional
program, forming striated contractile myofibers and
participating in muscle regeneration in vivo. DMD-
hiPSC-derived myoblasts show disease-related phe-
notypes with patient-to-patient variability, including
aberrant expression of inflammation or immune-
response genes and collagens, increased BMP/
TGFb signaling, and reduced fusion competence.
Furthermore, by genetic correction and pharmaco-
logical ‘‘dual-SMAD’’ inhibition, the DMD-hiPSC-
derivedmyoblasts and genetically corrected isogenicCel
This is an open access article under the CC BY-Nmyoblasts form ‘‘rescued’’ multi-nucleated myo-
tubes. In conclusion, our findings demonstrate the
feasibility of establishing a human ‘‘DMD-in-a-dish’’
model using hiPSC-based disease modeling.INTRODUCTION
Embryonic development has been successfully modeled in vitro
by differentiating human pluripotent stem cells (hPSCs), in-
cluding human embryonic stem cells (hESCs) and human
induced pluripotent stem cells (hiPSCs). This occurs by modu-
lating relevant signaling pathways via chemical compounds, as
demonstrated in the neuroectodermal, cardiac, and endodermal
lineages (Borowiak et al., 2009; Burridge et al., 2014; Chambers
et al., 2009; Di Giorgio et al., 2008). Combined with a strategy to
isolate homogenous populations, disease-specific hiPSC-
derived cells have facilitated our understanding of the pathogen-
esis of human genetic disorders by providing symptom-relevant
cell types in a patient-specific manner (Chen et al., 2014; Kiskinis
et al., 2014; Wainger et al., 2014). This has lead researchers to
validate potential therapeutic small molecules that can rescue
in vitro phenotypes (Brennand et al., 2011; de Boer et al., 2014).
However, efforts such as those mentioned above have not yet
been fully applied to the hiPSCs of muscular dystrophy, mainly
due to the absence of a successful strategy for isolatingl Reports 15, 2301–2312, June 7, 2016 ª 2016 The Author(s). 2301
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
expandable functional myoblasts. Previous efforts to derive
myogenic cells from hESCs and hiPSCs were based on the
ectopic expression of myogenic transcription factors, such as
PAX3, PAX7, and MYOD1, by viral gene delivery (Darabi et al.,
2012; Tedesco et al., 2012). Although this approach can produce
certain myogenic cells, the random integration of viral DNA can
jeopardize disease modeling and mask any unknown potential
disease phenotype. In addition, other previous methods rely on
animal-derived factors and require arduous long-term culture
(4 months or more) (Barberi et al., 2007). More importantly,
high-purity, disease-specific myoblasts must be isolated and
expanded to study their transcriptional profiles or functional
deficits. Considering the high disease prevalence and severity,
as well as a lack of meaningful therapies for most skeletal
muscle disorders, it is critical to develop a human cellular model
system.
One of the most common muscular dystrophies is Duchenne
muscular dystrophy (DMD), which affects approximately 1 in
5,000 live male births. DMD is caused by mutations in
DYSTROPHIN (Hoffman et al., 1987), and more than 1,000
different sequence variations in the culprit gene (http://www.
dmd.nl) have been discovered. PatientswithDMDhave heteroge-
neousdiseaseseveritydue tospecificDYSTROPHINmutationsas
well asmodifier genes, as demonstratedby awide range of loss of
ambulationandendof life (VoandMcNally, 2015).Althoughzebra-
fish, mouse, and dogmodels have providedDMD-related data on
pathogenesis, it is generally recognized that each of thesemodels
have limitations (Kornegay et al., 2012; Partridge, 2013). A DMD
study using mouse embryonic stem cells (mESCs) from a DMD
mousemodelwas published recently (Chal et al., 2015). However,
it is still questionablewhether any of themESC-based studies can
sufficientlymodel such varied severity in amutation-dependent or
patient-specific manner.
Humanized DMD models carrying patient-specific DYSTRO-
PHINmutations will be complementary to current animal models
of DMD. One such potential humanized DMD cell model is DMD-
specific hiPSCs. Here, we planned to establish a defined, robust,
and efficient system to direct hPSCs into myogenic specifica-
tion, demonstrating the feasibility of myoblast derivation from
DMD-specific hiPSCs. Recapitulation of the heterogeneous
severity of disease among patients could be a step toward
comprehensive mechanistic studies on DMD pathogenesis. In
addition, harnessing the potential of hiPSC technology may
lead to a more personalized approach for DMD treatment.
RESULTS
A Defined Myogenic Specification Platform Generates a
Pure and Functional Myoblast Population
To harness the potential of hPSCs, we developed a protocol to
direct hPSCs into the skeletal muscle lineage. As the somite is
an intermediate stage between hPSCs and myogenic progenitor
cells (Bentzinger et al., 2012; Deque´ant and Pourquie´, 2008) (Fig-
ure S1A), we generated a MESOGENIN1::eGFP reporter hESC
line with the CRISPR/Cas9 system (Mali et al., 2013) (Figures
S1B–S1D).MESOGENIN1 is a genetic marker for the pre-somite
mesoderm fate (Fior et al., 2012). Brief treatment (4 days after
day 0 of differentiation) with CHIR99021, a GSK-3b inhibitor2302 Cell Reports 15, 2301–2312, June 7, 2016(Bennett et al., 2002), significantly increased expression of
MESOGENIN1::eGFP (80.8% ± 11.3% cells out of total cells in
a dish), TBX6 (67.4% ± 10.4%), and PAX3 in a dose-dependent
manner (Figures S1E–S1G) at day 4 and gave rise to myogenic
cells expressing MyHC (MF20), MYOG, and MYOD at day 40
(30.4% ± 13.7%, 37.7% ± 5.78%, and 30.4% ± 13.70%, respec-
tively) (Figure S1H). CHIR99021 appeared to activate the canon-
ical WNT signaling pathway, confirmed by b-catenin transloca-
tion into the nucleus (Figure S1I). Further data analysis
suggests that WNT activation and inhibition of the PI3K pathway
(Figures S1J–S1L) are sufficient for induction ofMESOGENIN1::
eGFP from hPSCs. These data are partially explained by
fostering myogenic specification from somite cells as well as
enhanced WNT activation (Figures S1M–S1P), and they are in
agreement with results of studies from other groups (Borchin
et al., 2013; Chal et al., 2015; Wang et al., 2007; Xu et al.,
2013). To increase the speed and efficacy of myogenic specifi-
cation, we found that treatment from day 4 to day 12 with
DAPT, a g-secretase inhibitor that blocks Notch signaling (Dovey
et al., 2001) (Figure 1A), promoted a robust and fast myogenic
differentiation. At day 30, 63.6% ± 9.68% of cells were MF20+,
and 61.5% ± 11.0% were MYOGENIN+ (Figures 1B and S1Q–
S1U), which is consistent with data from recent rodent studies
(Mayeuf-Louchart et al., 2014; Mourikis et al., 2012).
The resulting ‘‘CHIR99021-DAPT culture’’ in defined N2media
(Figure 1A) was tested on multiple hiPSC lines (>10 different
clones) and consistently resulted in differentiation of myoblasts
into multinucleated and spontaneously contractile myotubes
(Movies S1, S2, and S3; skeletal muscle cells derived from
hESC [H9] and normal hiPSCs [GM01582, GM02036]). The
hESC- and hiPSC-derived myotubes in CHIR99021-DAPT cul-
ture were further characterized by transmission electron micro-
scopy. The spontaneously contracting myotubes showed a
highly organized structure, including intact sarcomeres with
distinct Z-lines, M-lines, and I-bands (Figures 1C and S1V).
To determine the in vivo engraftment potential, we trans-
planted the dissociated CHIR99021-DAPT culture cells into the
injured tibialis anterior (TA) muscle of NOD-Rag1nullIL2rgnull
(NRG) mice. 6 weeks after transplantation, immunohistochem-
istry performedwith two human specific antibodies (human-spe-
cific Lamin A/C and human-specific Laminin) confirmed that the
transplanted human myoblasts formed extensive myofibers
without tumor formation (n = 33 mice) (Figure 1D, left). Impor-
tantly, a small proportion of human nuclei (human Lamin A/C +)
were also observed to express PAX7 underneath a human Lam-
inin basal lamina, indicating that some of the transplanted cells
occupied the niche of adult muscle stem cells, known as satellite
cells (Figure 1D, right). In contrast, no expression of human anti-
gens was detected in sham-transplanted control mice.
To determine the presence of fusion-competent myoblasts,
we re-plated the dissociated cells from the CHIR99021-DAPT
culture (days 25–30). Most of the attached and surviving cells
were mono-nucleated at day 2 after re-plating, and they could
form multi-nucleated myotubes at day 10 after re-plating with
typical striations and expression of myotube marker proteins,
including DYSTROPHIN (35.55 ± 6.4%cells were positive), TITIN
(37.5% ± 5.25%), and a-ACTININ (40.8% ± 9.7%, sarcomeric or-
ganization) (Figures 1E, 1F, and S1W).
Figure 1. Characterization of Myogenic Cells Derived from hPSCs
(A) Schematic illustration of myogenic specification of hPSCs with two chemical compounds.
(B) Myogenic differentiation after CHIR99021 and DAPT treatment, determined (day 30) by expression of myosin heavy chain (MF20) and myogenic regulatory
factors (MYOG).
(C) Transmission electron micrograph showing sarcomeres in contractile, mature myotubes derived from hESCs (WA09).
(D) Left: formation of numerous human, multi-nucleated myofibers by transplanted hPSC-derived skeletal muscle cells, 4 weeks after injection, confirmed with
two human specific antibodies (LAMIN A+C and LAMININ). Inset shows enlarged image of a single myofiber. Right: co-expression of PAX7+ and hLAMIN A+C
nucleus (white arrow) in human myofiber expressing hLAMININ.
(E) Formation of hESC- and hiPSC-derived multinucleated myotubes expressing DYSTROPHIN, TITIN, and a-ACTININ (with striation).
(F) Quantification of DYSTROPHIN, TITIN, and a-ACTININ expressing cells.
n = 3–10. Scale bars represent 50 mm, except (C) (500 hm) and the inset of (D) (5 mm).Isolation of fusion-competent myoblasts could pave the
way for disease modeling. As shown in Figures 1E, 1F, and
S1T, our CHIR99021-DAPT culture contains fusion-compe-
tent myoblasts as well as differentiated myotubes with well-
organized sarcomeres. To isolate myoblasts, we tested multi-
ple cell surface markers to facilitate fluorescence-activated
cell sorting (FACS) purification of myoblasts in CHIR99021-
DAPT culture. Positive selection with the NCAM (5.1H11) anti-
body (Webster et al., 1988) combined with negative selection
using the HNK1 antibody (Figures 2A and S2A) enriched skel-
etal muscle progenitor cells. This determination was based
upon significantly increased expression levels of MYOD1,
MYOG, and MyHC (Figures 2B, 2C, S2B, and S2C) in
the NCAM+/HNK1 fraction over the NCAM or NCAM+/HNK1+ fractions. Furthermore, single-cell qRT-PCR showed
that 98% (95 out of 96) of single NCAM+/HNK1 cells had
higher expression of MYOG and PAX7 than a sample of hu-
man fetal skeletal muscle and undifferentiated hESCs (Figures
S2D and S2E).
To identify the global mRNA profiles, we performed unbiased
gene expression analysis, which showed a hierarchical clus-
tering between the hPSC-derived NCAM+/HNK1 population
and fetal skeletal muscle (18 to 19 weeks of gestation) over un-
differentiated hESCs (Figure 2D). Transcripts highly enriched in
the NCAM+/HNK1 fraction included key markers of skeletal
muscle structure development (Millay et al., 2013; Wang et al.,
1979; Wohlgemuth et al., 2007) and key transcription factors
(L’Honore´ et al., 2007; Martin et al., 1993) (Figure 2E). GeneCell Reports 15, 2301–2312, June 7, 2016 2303
Figure 2. FACS Purification of Functional Myoblasts Cells
(A) Representative FACS plots for NCAM+/HNK1 cell population.
(B and C) qRT-PCR confirming expression of MYOD1 (B) and MYOG (C) in post-sorted cells.
(D) Clustered heatmap of global gene expression values comparing NCAM+/HNK1, human fetal skeletal muscle (18 to 19 weeks), and undifferentiated hESCs
(hESC), using Partek program (Pearson correlation). The plot is rank-ordered with pluripotent-specific genes on the left and skeletal muscle specific genes on the
right.
(E) Graph of the changes in gene expression levels as assessed by microarray analysis: increased in NCAM+/HNK1 (green) and decreased in undifferentiated
hESCs populations (yellow) compared to each other.
(F) Gene ontology (DAVID) analysis of upregulated transcripts in NCAM+/HNK1 population.
****p% 0.0001. One-way ANOVA followed by Newman-Keuls test. n = 3–5. All values represent mean and SD.ontology (GO) analysis revealed statistically significant over-rep-
resentation of GO terms among the upregulated genes in the
NCAM+/HNK1 fraction, including those of ‘‘embryonic skeletal
muscle development’’ (p = 4.523 1022), ‘‘muscle structure sys-
tem’’ (p = 2.10 3 1029), and ‘‘muscle contraction’’ (p = 2.61 3
1024) (Figure 2F). The gene expression array results were
confirmed by qRT-PCR with primer sets for selected genes (Fig-
ure S2F). The isolated NCAM+/HNK1 population wasmarkedly
proliferative during exposure to expansion-permissive condi-
tions for 6 weeks and could be easily expanded up to hundreds
of millions of cells (a population doubling time for hESC and
hiPSCs of 50.8 ± 18.5 hr and 47.9 ± 17.0 hr, respectively) (Fig-
ure S2G). The hiPSC-derived myoblasts could be successfully2304 Cell Reports 15, 2301–2312, June 7, 2016cryopreserved and maintained their myotube-forming potential
upon thawing (Figure S2H).
Generation of Myoblasts from hiPSCs of Duchenne
Muscular Dystrophy
To test whether ourmyoblast specification and isolation protocol
could be applied to hiPSCs derived from DMD patients, we
generated patient-specific hiPSCs from five different geno-
types (Table 1 and Figures S3A–S3E). In order to find transcrip-
tional changes between NCAM+/HNK1 cells (Figure S3F) of
DMD-hiPSC (GM05169, exon 4–43 deletion) and the control
(healthy)-hiPSC population, we applied unbiased global tran-
scription analysis and subsequent GO analysis (Figure 3A). The
Table 1. Details of Fibroblasts Used for Generation of DMD-
hiPSC Lines
ID in Coriell Catalog Description Mutations Age (yr)






GM04327 DMD (duplication) EX5-7DUP 23
GM03781 DMD (deletion) EX3-17DEL 11
GM03783 DMD (deletion) EX3-17DEL 10differentially upregulated genes in NCAM+/HNK1 cells of the
DMD-hiPSC population (hereafter referred to as DMD-myo-
blasts) were largely classified into wound healing, inflammation,
and signaling pathways. To validate these findings in different ge-
notypes and mutations in DMD patient hiPSCs (Table 1), we
chose a set of significantly upregulated genes in DMD-myoblasts
(fold changeR 2-fold; corrected p value of 0.05), which included
17 over-represented genes in the five categories mentioned
above, to perform qRT-PCR analysis. Using additional DMD-
hiPSC lines with different mutations (two exon 3–17 deletion,
one exon 5–7 duplication, and one nonsense mutation; at least
three iPSC clones per genotypes), we generated myoblasts
from each clone of DMD-hiPSC lines using previously mentioned
protocols (Figure S1) of myogenic specification and FACS
purification. No DYSTROPHIN protein was detectable in the
DMD-hiPSC-derivedmyoblasts using western blot and immuno-
histochemistry (Figures S3G and S3H), whereas control hPSC-
derived myoblasts showed detectable levels of DYSTROPHIN
expression (Figure S3I). Furthermore, DMD-hiPSC-derived myo-
blasts showed distinctively different myogenic marker gene
expression patterns than fibroblasts (Figure S3J). In vivo trans-
plantation experiments with two different mouse strains, NOD-
Rag1nullIL2rgnull mice (immuno-deficient healthy recipients) and
NOD-SCID-IL2rgnull-mdx4Cv mice (immuno-deficient mdx mice
lacking dystrophin) (Arpke et al., 2013), demonstrated that
myogenic culture of DMD-hiPSCs could participate in muscle
regeneration processes after cardiotoxin injury (Figure S3K).
The different DMD-myoblasts each had varying levels of gene
expression in the DMD qRT-PCR analysis, although all assayed
genes were aberrantly expressed in DMD-myoblasts compared
to control hiPSCs. In particular, all lines showed upregulated
expression of BMP4 and TGFb genes (Figure 3B). Increased
levels of BMP4 and TGFb signaling were confirmed by a signif-
icantly increased nuclear localization of phosphorylated SMAD
(pSMAD 1/5 and 2/3) in DMD-myoblasts compared to control
myoblasts (Figures 3C, 3D, and S3L). We also found increased
protein expression levels of interleukin 6 and 8 and collagen 3 in
DMD-myoblasts, whereas the expression level of collagen 1 re-
mained unchanged (Figures 3E–3G and S3M). Interestingly,
myoblasts from individual DMD-hiPSC lines showed different
patterns. For example, they all had higher levels of nuclear
localized phospho-SMAD 1/5 and 2/3, but expression levels
of interleukin 6 and 8 and collagen 3 were varied among
different DMD-hiPSC lines. Furthermore, analysis of myotube
formation as measured by the fusion index (the ratio of number
of nuclei inside DESMIN+ myotubes to the number of totalnuclei3 100) showed that all the DMD-myoblasts from different
DMD-hiPSC lines had decreasedmyotube formation compared
to control myoblasts (p < 0.0001) (Figures 3H and 3I). To test
whether this observation was specific to the DMD-myoblasts,
we compared the hiPSC lines we developed from facioscapulo-
humeral muscular dystrophy (FSHD) and amyotrophic lateral
sclerosis (ALS, C9ORF72 mutation) (Figures S3A–S3D).
Myoblast cultures derived from hiPSC lines of FSHD and ALS
could form myotubes with expression of disease biomarkers
(Figures S3N–S3P). As shown in Movie S4, we often found
spontaneously twitching cells during myogenic specification
of ALS-hiPSCs, but we have not found any spontaneously con-
tracting cells during DMD-hiPSC differentiation (n = 71 repeats).
To confirm our findings, we used a previously published proto-
col (Shelton et al., 2014) and showed robust myogenic specifi-
cation (comparable levels to our protocol) in healthy control
hPSCs (Figures S3Q and S3R). However, there were differential
transcriptional profiles of DMD-hiPSCs (Figure S3S). In addi-
tion, the DMD-hiPSC-derived myoblasts showed aberrant my-
otube formation with many branched arms, reminiscent of
another group’s study using mdx mESCs (Chal et al., 2015)
(Figure S3T).
Our data suggest that myoblasts of DMD-hiPSCs display tran-
scriptional, translational, and functional in vitro phenotypes. Af-
ter confirming the transcriptional and translational phenotypes
of DMD-myoblasts, we hypothesized that theremight be a signif-
icant correlation among the list of aberrantly expressed genes
(Figure 3B). A correlation heatmap was generated using the
gene-to-gene Pearson correlations for the 16 genes initially cho-
sen from global transcriptional analysis (Figure 3J). Among
the positively co-correlated genes, SPP1, BMP4, CASPASE1,
BMP2, and TGFb3 formed the clearest cluster. Furthermore,
additional correlation analysis (Table 2) confirmed a statistically
significant correlation (p value, 0.0211  <0.0001) between
SPP1 and the other 12 genes. Interestingly, SPP1 (Osteopontin)
has been shown to be a potent genetic modifier of disease
severity in DMD (Pegoraro et al., 2011; Zatz et al., 2014).
Rescuing Phenotypes of DMD-Myoblasts by Genetic
Restoration of DYSTROPHIN
To restore the genetic deficiency of the exon 4–43 deletion of
one of the DMD mutations, we employed the human artificial
chromosome (HAC) technique (Kazuki et al., 2010). The HAC
technique was used because conventional gene targeting ap-
proaches were not feasible due to the size of the DNA to be
delivered. We reprogrammed genetically corrected DMD fibro-
blasts (GM05169 carry HAC with 2.4 Mb entire genomic
DYSTROPHIN, renamed DF160) into hiPSCs (Figures S4A and
S4B). After confirmation of normal karyotype and presence of
the HAC (Figures S4C and S4D), the myogenic culture of cor-
rected DMD-hiPSCs was transplanted into NRG and NSG-
mdx4Cv mice. We found comparable levels of human myofiber
formation in both in vivo environments (Figures S4E–S4G). These
data are supported by recent reports from other groups (Boldrin
et al., 2015; Dumont et al., 2015). FACS-purified myoblasts from
the corrected DMD-hiPSCs (referred to as ‘‘corrected DMD-
myoblasts’’) showed (Figure 4A) reversed gene expression
profiles in our DMD qRT-PCR assay (Figure 4B). Using anCell Reports 15, 2301–2312, June 7, 2016 2305
Figure 3. DMD-hiPSC-Derived Myoblasts Show Dis-
ease-Related Phenotypes
(A) Unsupervised clustered heatmap of global gene expres-
sion values comparing control (CTRL) and DMD-hiPSC-
derived myoblasts (DMD-myoblasts) (after NCAM+/HNK1
purification) and gene ontology (DAVID and IPA/Ingenuity)
analysis of transcripts that were upregulated in DMD as
opposed to downregulated in control (left lower panel) tran-
scripts in control myoblasts.
(B) Heatmap of DMD qRT-PCR analysis with selected repre-
sented genes. The value is acquired after normalization by
GAPDH value and fold change by the mean value of control
hiPSCs. Each box represents different clones of the genotypes
and biological repeats of the myoblast isolation.
(C–G) Nuclear localization of phosphorylated SMAD (pSMAD)
proteins and expression levels of interleukin 6 and 8, and
collagen 3 found in myoblasts (after NCAM+/HNK1 purifi-
cation) of multiple DMD-hiPSC lines.
(H and I) Impaired myotube formation in DMD-myoblasts.
(H) Representative images showing DESMIN staining. (I)
Decreased level of fusion index (calculated as ratio of number
of nuclei inside myotubes to the number of total nuclei 3 100
after myotube formation).
(J) Pearson correlation heatmap among the genes listed in (B)
shows the Pearson correlation coefficients of expression
levels of each selected gene among DMD-myoblasts of five
different patient hiPSC lines. Color key from brown to purple
indicates correlation from low to high, respectively. The
normalized expression values of those genes in were used for
calculation of correlation matrix.
*p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001. One-way
ANOVA followed by Newman-Keuls test.N.S., not significantly
different. n = 3–11. All values represent mean and SD. Scale
bar in (H) represents 50 mm.
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Table 2. Correlation between SPP Expression and Other ‘‘Potentially Culprit Genes’’
r 95% Confidence Interval R squared p (Two-Tailed) p Value Summary
Significant?
(Alpha = 0.05)
SPP1 versus BMP2 0.974 0.9071 to 0.9929 0.9486 <0.0001 **** Yes
SPP1 versus BMP4 0.9851 0.9461 to 0.9959 0.9704 <0.0001 **** Yes
SPP1 versus TGFB1 0.6537 0.8927 to 0.1278 0.4274 0.0211 * Yes
SPP1 versus TGFB2 0.8336 0.9520 to 0.4978 0.6948 0.0008 *** Yes
SPP1 versus TGFB3 0.9703 0.8945 to 0.9919 0.9415 <0.0001 **** Yes
SPP1 versus TNFRSF21 0.7023 0.2151 to 0.9096 0.4932 0.0109 * Yes
SPP1 versus EGF 0.4151 0.2085 to 0.7987 0.1723 0.1797 ns No
SPP1 versus CASPASE1 0.9839 0.9416 to 0.9956 0.968 <0.0001 **** Yes
SPP1 versus CASPASE4 0.9397 0.7942 to 0.9833 0.8831 <0.0001 **** Yes
SPP1 versus COL1A1 0.2073 0.6981 to 0.4161 0.04297 0.518 ns No
SPP1 versus COL3A1 0.849 0.5365 to 0.9567 0.7208 0.0005 *** Yes
SPP1 versus COL4A5 0.7275 0.2637 to 0.9181 0.5293 0.0073 ** Yes
SPP1 versus COL4A6 0.8846 0.6312 to 0.9674 0.7826 0.0001 *** Yes
SPP1 versus IL6 0.8993 0.6725 to 0.9717 0.8088 <0.0001 **** Yes
SPP1 versus IL8 0.2953 0.3354 to 0.7433 0.08722 0.3514 ns Nounsupervised hierarchically clustering approach, gene expres-
sion profiles of corrected DMD-myoblasts were closer to that
of control (healthy) myoblasts but further from uncorrected
DMD-myoblasts. The increased levels of nuclear localization
of phosphorylated SMAD (pSMAD) and expression of inter-
leukin 6 and 8 and collagen 3 were reversed in the corrected
DMD-myoblasts (NCAM+/HNK1 cells) (Figures 4C–4G),
whereas the expression level of collagen 1 remained unchanged
(Figure S4H). Additionally, using m-DYSTROPHIN (Scott et al.,
2002) and three different gene correction approaches (18 bp
ExonSkip, knockin by TALEN, and knockin by CRISPR) (Li
et al., 2015), we found that the transcriptional and functional
aberrations were partially rescued in DMD-myoblasts (NCAM+/
HNK1 cells) (Figures S4I–S4L). More importantly, the fusion in-
dex of the corrected DMD-myoblasts was significantly higher
(p < 0.0001) than that of DMD-myoblasts, but it was significantly
lower than that of control myoblasts (p < 0.05) (Figure 4H). Unlike
uncorrected DMD-hiPSCs, which had a limited level of DESMIN
expression (Figure 3H), the multinucleated myotubes of cor-
rected DMD-hiPSCs expressed DYSTROPHIN, DESMIN, and
MYOSIN LIGHT CHAIN-1 (Figure 4I).
Pharmacological Inhibition of SMAD Signaling
Facilitates Formation of ‘‘Rescued’’ Myotubes
To find pharmacological rescue of the in vitro phenotypes, we
focused on aberrant BMP and TGFb signaling indicated by
increased nuclear localization of pSMAD proteins in DMD-
myoblasts (Figures 3C and 3D). We detected increased levels
of BMP4 in the conditioned media (CM) of DMD-myoblasts
(Figure S5A). Furthermore, we tested the effects of CM from
DMD-myoblasts on control myoblasts and found significantly
decreased myotube formation and significantly decreased
expression levels of MYOG and MYOD1 (Figures S5B and
S5C) compared to those of the CM from control-myoblasts.
The effects of CM from DMD-myoblasts were reproduced by
treatment with BMP4 protein in the culture media, which werereversed by treatment with ‘‘dual-SMAD’’ inhibition com-
pounds (Figure S5D) (LDN+SB: LDN193189 and SB431542).
These data suggest that pharmacological rescue can mitigate
the effects of inhibitory cytokines in DMD-myoblasts. We
tested this hypothesis in DMD-myoblasts and found that treat-
ment with the dual-SMAD inhibition compounds (LDN+SB)
reversed the levels of increased nuclear localization of pSMAD
protein and expression of interleukin 6 and 8 and collagen 3
(Figures 5A–5E). In addition, the LDN+SB treatment rescued
the fusion defects in DMD-myoblasts with four out of five muta-
tions (Figure 5F), but it did not reverse the fusion defects in
DMD-myoblasts with the exon 5–7 duplication (GM04327).
These data indicated that pharmacological inhibition of
SMAD signaling could rescue DMD-related phenotypes in
DMD-myoblasts of some patients and restore the functional
deficit, albeit with less efficiency.
Next, we determined whether the genetically corrected DMD-
myoblasts could fuse with DMD-myoblasts in vitro, thus
mimicking the microenvironment of a DMD patient receiving a
transplant of genetically correct autologous myoblasts. Geneti-
cally corrected DMD-myoblasts (DF160) were transfected with
eGFP (marking the cytoplasm as green), and uncorrected
DMD-myoblasts (GM05169) were transfected with nuclear RFP
(marking the nuclei as red). The two cell lines were then co-
cultured to permit myotube fusion (Figure 5G). Some of the
GFP+ myotubes contained RFP+ nuclei, demonstrating the for-
mation of rescued myotubes arising from fusion of corrected
DMD-myoblasts and non-corrected DMD-myoblasts. The num-
ber of nuclei participating in the formation of rescued myotubes
was calculated with a ‘‘rescued fusion index’’ (calculated as the
ratio of number of nuclei inside GFP+/RFP+ rescued myotubes
to the number of total nuclei 3 100 after myotube formation).
Importantly, the rescued fusion index between corrected
DMD-myoblasts and non-corrected DMD-myoblasts was signif-
icantly increased upon treatment with dual-SMAD inhibition
compounds (Figure 5H).Cell Reports 15, 2301–2312, June 7, 2016 2307
Figure 4. Genetic Rescue of DMD-Related
Features
(A) Introducing human artificial chromosome
(HAC) carrying full-length human DYSTROPHIN
gene (DYSTROPHIN-HAC) into fibroblasts (before
GM05169, after introducing, DF160), followed by
reprogramming into hiPSCs, and subsequent
myogenic specification into corrected DMD-myo-
blasts.
(B) Unsupervised clustered heatmap of DMD qRT-
PCR assay with corrected myoblasts (after
NCAM+/HNK1 purification) showed reversed
transcription profile, using Partek program
(Euclidean distances as the distance measure).
(C–G) Nuclear localization of phosphorylated
SMAD (pSMAD) proteins and expression levels
of interleukin 6 and 8, and collagen 3 found in
myoblasts (after NCAM+/HNK1 purification) of
rescued hiPSC line (DF160). Impaired myotube
formation in DMD-myoblasts, determined at day
10 after myotube induction.
(H and I) Increased fusion rate (H) and formation
of myotubes from DF160 hiPSCs, expressing
DYSTROPHIN, DESMIN, and MYOSIN LIGHT
CHAIN-1 (I).
*p % 0.05, **p % 0.01, ***p % 0.001, ****p %
0.0001. One-way ANOVA followed by Newman-
Keuls test. n = 3–6. All values represent mean
and SD.DISCUSSION
We have demonstrated that a myogenic specification protocol
employing two small molecules (CHIR99021 and DAPT) is suffi-
cient to direct multiple hPSC lines (13 different genotypes,
including 3 different disease-specific hiPSC lines) into myogenic
lineages in approximately 30 days. The hPSC-derivedmyoblasts
can be isolated by FACS, and their functional and molecular
characterization confirmed their myogenic properties, such as
authentic myogenic transcriptional program, formation of stri-
ated contractile myofibers, highly organized ultra-structure,
and in vivo engraftment capability. Furthermore, this system
was readily applied to DMD-specific hiPSCs with multiple ge-2308 Cell Reports 15, 2301–2312, June 7, 2016netic variations (three different deletion
types, one duplication, and one non-
sense mutation), successfully generating
DMD-myoblasts presenting DMD-related
phenotypes including altered transcrip-
tional profiles, aberrant intracellular
signaling, and defective myotube forma-
tion. These DMD phenotypes were
partially reversed by genetic and pharma-
cological approaches, resulting in the for-
mation of rescued myotubes between
DMD-myoblasts and their genetically cor-
rected isogenic ones. Our myoblast puri-
fication and defined culture methods
have enabled us to set up a humanized
DMD model system to study multiple as-
pects of DMD pathogenesis.
The induction of myogenic specification of hESCs and hiPSCs
by CHIR99021 treatment has previously been reported by other
investigators (Shelton et al., 2014). However, the underlying
mechanisms of CHIR99021 activity remain unresolved. In our
studies using the MESOGENIN1::eGFP reporter hESC line,
which was generated by CRISPR/Cas9-mediated gene-target-
ing, we found that activation of the WNT pathway and inhibition
of the PI3K pathway are needed for directing hESCs and hiPSCs
into the somite stage (MESOGENIN1::eGFP+ population), sug-
gesting possible off-target effects of CHIR99021. Our data also
indicate that inhibition of the Notch signaling pathway is critical
to increase and accelerate the myogenic program of hESC/
hiPSC-derived somite cells, consistent with a recent study
Figure 5. Pharmacological Inhibition of SMAD Signaling Facilitates Formation of ‘‘Rescued’’ Myotubes
(A–F) The ‘‘dual-SMAD inhibition’’ compounds (LDN193189 + SB431542 = LDN+SB) treatment partially reverses the localization of phosphorylated SMAD
(pSMAD) proteins (A and B), expression levels of interleukin 6 (C) and 8 (D), collagen 3 (E), and myotube formation (F) in myoblasts (after NCAM+/HNK1 pu-
rification) of multiple DMD-hiPSC lines.
(G and H) GFP-labeled corrected DMD-myoblasts were co-cultured with RFP-labeled (nuclei localized) DMD-myoblasts for formation of rescued myotubes as
shown in two independent imageswith a single GFP-labeledmyotube containing RFP-labeled nuclei (G). (H) Ratio of rescuedmyotube formationwas significantly
enhanced upon treatment with LDN+SB. The ‘‘rescued fusion index’’ was calculated as the ratio of number of nuclei inside GFP+/RFP+ rescued myotubes to the
number of total nuclei 3 100 after myotube formation.
*p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001. One-way ANOVA followed by Newman-Keuls test, except (F), t test between DMSO and LDN+SB treatment
per genotype. n = 3–6. All values represent mean and SD. All scale bars represent 50 mm.(Mayeuf-Louchart et al., 2014) showing the significance of Notch
signaling on the fate decision processes of somite cells.
The myotubes generated using our culturing method were
often found to spontaneously contract in vitro and possessed
a highly systematized ultrastructure resembling that of in vivo
skeletal muscle. Indeed, in vivo experiments with the myogenic
cells of hESCs and hiPSCs demonstrated that they efficiently
participated in the process of murine muscle regeneration.
Importantly, a few transplanted human cells expressing PAX7
could be found in the satellite cell niche beneath the basal
lamina.
Another important finding in our current study is the establish-
ment of an isolation strategy of expandable myoblasts from a
heterogeneous hiPSCs culture. After approximately 30 days of
myogenic specification, we observed that the culture dishes
contained different types of cells, including spontaneously
twitching myofibers and myotubes, myoblasts, neurons, and fi-
broblasts. Among this diversity of cells, only some of them
were mono-nucleated myoblasts, which can be FACS-purified
by using NCAM and HNK1 antibodies. This FACS-purification
strategy was readily applied to multiple hiPSC lines, and theyields were comparable among different genotypes of hESCs
and hiPSCs, including DMD-hiPSCs. Furthermore, the FACS-
purified myoblasts can be expanded up to the hundreds of mil-
lions of cells, and they are easily cryo-preserved without losing
fusion competence. Combined with the xeno-free culture condi-
tion (defined media condition and compound based specifica-
tion), our protocol could be extended to large-scale compound
screening efforts and eventually to myoblast transplantation to
patients. Additional studies are necessary to reveal the detailed
molecular mechanisms governing the fate of each cellular stage
during human myogenesis, to comprehensively quantify PAX7+
human transplanted cells, and to monitor the long-term in vivo
behaviors of transplanted cells.
The DMD phenotypes in our present study, including
increased levels of BMP4 and TGFb signaling, aberrant expres-
sion of interleukins and the collagen genes, and fusion defects,
are supported by previous studies of DMD animal models and
myoblast cultures derived from DMD patient biopsy samples
(Cesana et al., 2011; Hartel et al., 2001; Jasmin et al., 1984;
Ng et al., 2012; Porter et al., 2002). Our present study implies
that secreted proteins might be responsible for the defectiveCell Reports 15, 2301–2312, June 7, 2016 2309
in vitro fusion of DMD-myoblasts. This finding was confirmed
in other experiments, such as treatment of control-myoblast
cultures with CM of DMD-myoblasts and co-cultures between
control-myoblasts and DMD-myoblasts, and it was partially
reversed by dual-SMAD inhibition. Importantly, upon dual-
SMAD inhibition, genetically corrected DMD-myoblasts can
form significantly increased numbers of rescued myotubes con-
taining nuclei of DMD-myoblasts. This rescued myotube culture
can be useful to study myoblast transplantation efficiency. More
than a decade ago, encouraged by successful transplantation
studies with mdx rodent models (Karpati et al., 1993; Partridge
et al., 1989), researchers attempted clinical trials of allogenic
myoblast transplantation for the treatment of DMD, but unfortu-
nately the results were disappointing (Karpati et al., 1993; Men-
dell et al., 1995; Skuk et al., 2007). Although more recent
attempts at human myoblast transplantation have achieved
some DYSTROPHIN expression, subsequent biopsies have
shown severe substitution by fibrosis and adipose tissue (Gus-
soni et al., 1992). There is little understanding as to why trans-
planted healthy myoblasts perform so poorly. Although rapid
cell death of transplanted healthy myoblasts (Fan et al., 1996)
and immune rejection have been suggested as reasons for low
transplant efficiency, an ‘‘unfavorable’’ or ‘‘hostile’’ microenvi-
ronment of the DMD host likely plays a significant role (Gussoni
et al., 1997). Although the low level of rescued myotube forma-
tion must be improved in future studies, our humanized DMD
myoblast model will be useful to reconstruct amicroenvironment
of DMD lesions receiving autologous and genetically corrected
myoblasts.
DMD-myoblasts from four patients were rescued upon phar-
macological dual-SMAD inhibition, but DMD-myoblasts with
exon 5–7 duplication (GM04327) were not able to be rescued.
These data suggest that patient-specific disparities in DMD
manifestation might be modeled in cell culture. It remains to be
determined why DMD-myoblasts originating from different pa-
tients display varied phenotypes and responses to pharmaco-
logical rescue; however, these data might be relevant to the var-
ied severity and progression of the disease symptoms among
patients and potentially the response to different therapeutic re-
agents (Pegoraro et al., 2011; Zatz et al., 2014). For example, our
data show that SPP1/Osteopontin expression levels in DMD-
myoblasts of different patients are significantly correlated with
most of the elevated expression levels of the ‘‘pathogenic candi-
date genes.’’ The relationship and potential mechanism between
the expression level of SPP1/Osteopontin and the clinical
severity and progression will be investigated in future studies
with DMD-myoblasts of large numbers of patient groups. In
particular, the genetic labeling (e.g., PAX7::GFP reporter DMD-
hiPSC lines) system will be very important for reliable isolation
of putative skeletal muscle stem cells from DMD-hiPSC lines.
Another interesting question is how DMD-myoblasts show
relevant phenotypes even before initiation of DYSTROPHIN pro-
tein expression. We have found that DYSTROPHIN transcription
occurs in myoblasts (Figure 3I) before myotube formation, but
the protein is not detected in the myoblast stage. Future studies
will be focused to uncover a possible unknown function of
DYSTROPHIN transcript or protein with more precise and sensi-
tive detection methodologies. Moreover, our in vivo experiments2310 Cell Reports 15, 2301–2312, June 7, 2016demonstrate that myogenic cells of DMD-hiPSCs can form hu-
man myofibers in healthy and mdx mouse models. Our in vitro
human model of DMD-myoblasts can be used to model the
cellular conditions of DMD patient pathology and will be useful
for understanding patient-specific disparities.
In conclusion, our data demonstrate the feasibility of gener-
ating and isolating expandable myoblasts from disease-hiPSCs
in a fast, efficient, and defined manner. We have gained insight
into the disease mechanism underlying DMD and present a




hESCs (H9, WiCell) and hiPSCs were cultured using standard protocols. The
hESC lines and hiPSC lines were cultured with mouse embryonic fibroblasts
(MEFs) (GlobalStem, or AppliedStemCell) pre-plated at 12,000–15,000 cells/
cm2. Medium contained DMEM/F12, 20% knockout serum replacement,
1 mM L-glutamine, 100 mM MEM non-essential amino acids, and 0.1 mM
b-mercaptoethanol. 10 ng/mL of FGF-2 was added after sterile filtration, and
cells were fed daily, and passaged weekly, using 6 U/mL dispase or
mechanically.
Generation of hiPSCs
The ALS patient fibroblasts (JH078 [C9ORF72] and GO013 [SOD1 A4V]) were
collected at Johns Hopkins Hospital with patient consent (IRB protocol: ‘‘Skin
biopsies to generate cell lines for study of Amyotrophic Lateral Sclerosis,’’
NA_00021979). Primary FSHD myoblasts (05Bdel) were obtained from the
Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center
for FSHD Research. Other fibroblasts (Table 1) were purchased from
Coriell with appropriate Material Transfer Agreement documents. Genetically
corrected DMD fibroblasts (DF160) were previously generated by transferring
the HAC with the entire DYSTROPHIN gene into DMD fibroblasts (GM05169).
Human cells were cultured in DMEMmedia containing 10% fetal bovine serum
(FBS). Fibroblasts were plated onto 24-well plates and then reprogrammed
with CytoTune-iPS Sendai Reprogramming Kit (Invitrogen) using our standard
protocol. After 9 days, cells were put onMEF feeder mediumwith Y-27632 and
then grown.
Myogenic Differentiation of hESCs and hiPSCs
MEF-conditioned N2 media is used for initial stage of myogenic specification.
Briefly, MEFs were plated at a density of 50,000 cells/cm2 in a T-225 flask.
The next day, the cells are washed once with PBS before adding 100 ml of
N2 medium. MEF-conditioned N2 media were harvested after 24 hr of incuba-
tion. For myogenic specification, hESCs and hiPSCs were rendered to single
cells using incubation of Accutase for 20 min, and plated on a gelatin-coated
dish for 10 min to remove MEFs. Non-adherent cells (mostly hESCs and
hiPSCs) were collected, counted, and plated on a 1% Geltrex-coated dish
(1 hr coating), at a density of 1.5 3 105 cells per well of a 24-well plate, in
the presence of filtered MEF-conditioned N2 media containing 10 ng/ml of
FGF-2 and 10 mM of Y-27632 (Cayman Chemical) (day 0). From the next day
(day 1) (60%  70% of confluence), N2 media with CHIR99021 (3 mM) was
added and media were changed at every other day. At day 4, N2 media with
DAPT (10 mM) treatment were added until day 12. BIO (30–250 nM), lithium
chloride (20 mM to 20 mM), Kenpallone (1–10 mM), SB 216763 (1–10 mM),
WNT-1 (10–100 ng/ml), WNT-3A (10–100 ng/ml), WNT-7A (10–100 ng/ml),
SBE13 hydrochloride (0.1 nM to 10 mM), and OTSSP167 hydrochloride
(0.1–10 nM) were tested during day 1 to day 4, as well as during day 4 to
day 8. The N2 medium contains DMEM/F12 powder, glucose, sodium bicar-
bonate, insulin, putrescine, progesterone, sodium selenite, and transferrin.
Statistical Analysis
All statistical analyses were performed using Graph Pad Prism software
(version 6.0). Values are from at least three independent experiments, with
multiple replicates each, and reported as mean ± SEM. Comparisons among
groups were performed either by one-way ANOVA followed by Newman-Keuls
test or by a t test. Statistical significance was assigned for p < 0.05.
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